ライフサイエンスコーパス: clinical end point

1 28-day all-cause mortality rate the primary clinical end point.

2 R slope predicts a treatment's effect on the clinical end point.

3 ccurately predicted treatment effects on the clinical end point.

4 0, 24, and 48 h after inoculation and at the clinical end point.

5 ime to PSA progression may also be important clinical end point.

6 mechanisms of action-of the treatment on the clinical end point.

7 scular (CV) mortality was defined as primary clinical end point.

8 he use of acute pain episodes as the primary clinical end point.

9 ng follow-up, 11 patients (1.8%) reached the clinical end point.

10 s too low to advocate its use as a surrogate clinical end point.

11 spectrum of improvement rather than a binary clinical end point.

12 nd nongenetic variables associated with each clinical end point.

13 AD for both biochemical failure (BF) and the clinical end points.

14 trial designs with appropriate biologic and clinical end points.

15 ve association was strongest for more severe clinical end points.

16 e trials were not powered for superiority in clinical end points.

17 the study design, setting, participants, and clinical end points.

18 lity or hospitalization and in key secondary clinical end points.

19 coronary intervention improves surrogate and clinical end points.

20 tive effects of oral diabetes agents on hard clinical end points.

21 associated with patient characteristics and clinical end points.

22 s, as are trials using surrogate rather than clinical end points.

23 erall survival, and correlation of EGFR with clinical end points.

24 e or placebo and followed for up to 8 yr for clinical end points.

25 he SR group, but no differences in the other clinical end points.

26 point was compared with pharmacokinetic and clinical end points.

27 with acute coronary syndrome were considered clinical end points.

28 impact of PSA decline was performed on these clinical end points.

29 oss treatment groups in any of the 3 primary clinical end points.

30 n treatment with respect to any of the major clinical end points.

31 o acetylcholine, preceded the development of clinical end points.

32 nificantly reduce the incidence of important clinical end points.

33 ndiabetic patients for both angiographic and clinical end points.

34 sures of biologic activity as surrogates for clinical end points.

35 reagents and chromogens; and differences in clinical end points.

36 out the association between such markers and clinical end points.

37 sequences of these changes on cardiovascular clinical end points.

38 ed to compare clinical and MRI parameters as clinical end points.

39 0.4% versus 0.4%, P=0.86), as were all other clinical end points.

40 s have measured or demonstrated an effect on clinical end points.

41 sive or conservative management and reported clinical end points.

42 ge-scale phase 3 clinical trials powered for clinical end points.

43 ng the profile of QoL outcomes to complement clinical end points.

44 ges of disease in order to establish optimal clinical end points.

45 have not been established as surrogates for clinical end points.

46 ted hospitalization (liver event) as primary clinical end points.

47 vide QoL metrics analogous to those used for clinical end points.

48 nd points followed by negative results using clinical end points.

49 integration of various biomarker assays and clinical end points.

50 tracted and analyzed according to predefined clinical end points.

51 FS) and overall survival (OS) were secondary clinical end points.

52 inal medications), myocardial perfusion, and clinical end points.

53 der to decipher disrupted biology in the two clinical end points.

54 ized by magnetic resonance imaging (MRI) and clinical end points.

55 points may be used as proxy for more robust clinical end points.

56 the present study was not powered to assess clinical end points.

57 were no differences in any of the secondary clinical end points.

58 often report surrogate outcomes rather than clinical end points.

59 ssion-free survival, and overall survival as clinical end points.

60 f conjugate vaccination in studies examining clinical end points.

61 Of 23 prespecified secondary clinical end points, 18 showed no significant difference

62 rt positive findings (67%) than trials using clinical end points (54.1%; P = .02).

63 Solitaire was also observed in the secondary clinical end point (90-day shift in modified Rankin Scal

64 the ramipril group had a 38% reduced risk of clinical end points (95% CI, 13%-56%), a 36% slower mean

65 ated treatment effect, the importance of any clinical end point achieved, and whether patients in the

66 treatment is associated with lower rates of clinical end points, additional to effects of blood pres

67 Pooled estimates for major clinical end points (all-cause mortality, myocardial inf

68 ectiveness of pressure therapies in reducing clinical end points, although 1 trial supported the bene

69 nsiderations for a meta-analysis of MRD as a clinical end point and evaluates MRD-negativity as an ea

70 f treatment effects on both the intermediate clinical end point and OS.

71 n of treatment effects on GFR slope with the clinical end point and to test how well the GFR slope pr

72 ted models were developed for four candidate clinical end points and cost.

73 ot improve infectious complications or other clinical end points and may be harmful as suggested by i

74 of study quality, as well as lack of similar clinical end points and measures of magnitude of benefit

75 ry PCI is not associated with any benefit on clinical end points and might increase the risk of strok

76 areas of clinical equipoise, and analysis of clinical end points and patient harms.

77 These findings provide optimized clinical end points and sample size estimates to inform

78 ategies that had been evaluated the most for clinical end points and showed modest associations with

79 This article discusses specific clinical end points and their advantages and disadvantag

80 n target-vessel failure at 9 months (primary clinical end point) and a 50% reduction in binary resten

81 e lack of power to sufficiently examine hard clinical end points, and a potential over-reliance on us

82 Data on use of hormonal contraception, clinical end points, and potential confounders were obta

83 A clinical events committee adjudicated clinical end points, and quantitative angiography was pe

84 d trial, we assessed beta-cell preservation, clinical end points, and safety in children and adolesce

85 effectiveness against hospitalization, other clinical end points, and safety.

86 ion about patient population, interventions, clinical end points, and study design were extracted, an

87 ical end points, association between IBF and clinical end points, and the mediating effect of IBF on

88 lowing: intention-to-treat analyses, data on clinical end points, and trials comparing nitrofurazone-

89 randomized comparative trials, and important clinical end points are assessed only after decades of f

90 Although data on clinical end-points are lacking, this is likely to be a

91 As compared with blinded adjudication, clinical end point ascertainment from queries of the Nat

92 Clinical end points assessed during a 3-month follow-up

93 Analyses with other clinical end point assessments, as well as analyses with

94 applied to evaluate LTAD benefit on IBF and clinical end points, association between IBF and clinica

95 The primary outcome was a composite clinical end point at 1 year comprising change in New Yo

96 nt relationship between post-PCI FFR and the clinical end point at 30-day follow-up ( P=0.636).

97 The updated clinical end points at 2 years for the parent trial conf

98 and at 3 months, peak of cardiac biomarkers, clinical end points at 3 months, and adverse events.

99 Patients receiving stavudine reached clinical end points at a rate of 26 per 100 person-years

100 nts, and the mediating effect of IBF on LTAD clinical end point benefits.

101 no significant differences in the coprimary clinical end point between the SEV and BEV groups (9.4%

102 appear to be any late effect of tirofiban on clinical end points between day 2 and 6 months.

103 SVR is a relevant clinical end point, but further analyses are required to

104 time of repeat angiography from the primary clinical end point by as long as possible.

105 Some of its nonspecificity for clinical end points can be ascribed to cross-reactivity

106 eatment efficacy in randomized trials before clinical end points can be evaluated.

107 though quality of life (QOL) is an important clinical end point, cancer drugs are often approved base

108 eeding events were formally adjudicated by a clinical end point classification group.

109 e investigators and adjudicated by a blinded clinical end point committee.

110 nical outcomes were adjudicated by a blinded clinical end points committee.

111 Mode of death as centrally adjudicated by a clinical end points committee.

112 All deaths were reviewed by a clinical end-point committee, and the mode of death was

113 all deaths, were adjudicated as to cause by clinical end points committees blinded to treatment assi

114 flammatory response as well as the composite clinical end point compared with surgical necrosectomy.

115 The composite coprimary clinical end point comprised death, disabling stroke, or

116 The prespecified composite clinical end point comprised new-onset sustained tachyar

117 Clinical end points comprised major adverse cardiac even

118 e combinations that most effectively provide clinical end-point data in RCTs.

119 c RCT, claims and EHR data provided the most clinical end-point data when compared with participant-r

120 he secondary end point was freedom from hard clinical end points (death, AMI recurrence, or stroke),

121 Of the clinical end points, death could be modeled most accurat

122 on between these genotypes and the following clinical end points: development of premature ovarian fa

123 gs suggest that equal weights in a composite clinical end point do not accurately reflect the prefere

124 at 3 months after randomization, and on the clinical end point (doubling of serum creatinine, GFR<15

125 ical mechanisms underlying patient-preferred clinical end points (eg, independence, quality of life)

126 Clinical end points evaluated included overall survival,

127 ds of borderline statistical significance in clinical end points favoring dual-chamber pacing were ob

128 Autoimmune diabetes is the clinical end point for a sequential cascade of immunolog

129 d higher percentage of subjects reaching the clinical end point for treatment (<=4 sites with PD >=5

130 II/III trials what are the most appropriate clinical end points for anti-signaling molecules such as

131 nsitive to disease progression are needed as clinical end points for future treatment trials in Starg

132 can Airway Collaborative consensus regarding clinical end points for rigorous study of novel therapie

133 syncytial virus (RSV) to inform selection of clinical end points for RSV vaccine efficacy trials.

134 ineering strategies enables LLMs to identify clinical end points from EHRs with an accuracy that surp

135 ther with results for eosinophil density and clinical end points from the main trial, these data supp

136 tronic health record data, patient report of clinical end points had low sensitivity for myocardial i

137 l validation of HIV-1 RNA as a predictor for clinical end points has implications for the use of HIV-

138 nd other estrogen-sensitive intermediate and clinical end points has not yet been established.

139 val end points, surrogates, and intermediate clinical end points have all been used to measure outcom

140 reased mortality rate driven by two distinct clinical end points: histological transformation and ear

141 The VE curve describes how VE against the clinical end point (HZ) varies across participant subgro

142 to determine the performance of intermediate clinical end points (ICEs) as surrogate end points for O

143 imus-eluting stents (DP-EES) for a composite clinical end point in a population with minimal exclusio

144 hange in peak expiratory flow as the primary clinical end point in airway stenosis.

145 on microperimetry may serve as a functional clinical end point in future human treatment trials for

146 ustule and dermis of samples obtained at the clinical end point in the human model of infection.

147 ificant improvement in the composite primary clinical end point in the RITZ-4 trial.

148 zes, GFR slope may be a viable surrogate for clinical end points in CKD RCTs.

149 -term functional status better than standard clinical end points in ICU studies and may serve as a pa

150 centration was significantly associated with clinical end points in participants with impaired kidney

151 t that image analysis can be used to predict clinical end points in patients receiving ICI.

152 beta-blockade is effective in reducing major clinical end points in patients with and without diabete

153 The beneficial effects of digoxin on common clinical end points in patients with HF were similar, re

154 eta42 and brain Abeta-PET with cognitive and clinical end points in randomized trials of anti-Abeta d

155 etween increasing concentrations of cTnI and clinical end points in the total study cohort (adjusted

156 s trial and the significantly higher rate of clinical end points in the zidovudine monotherapy group,

157 The primary clinical end point included cardiovascular death, resusc

158 Secondary clinical end points included a predefined composite end

159 Clinical end points included progression-free survival (

160 Clinical end points included safety and clinical remissi

161 Clinical end points included safety and clinical remissi

162 Secondary clinical end points included the durability of operation

163 Clinical end points included the presence of paravalvula

164 Methods and Results Data on clinical end points including neurological events <=30 d

165 There were 23 secondary clinical end points, including all-cause hospitalization

166 tors, would improve a comprehensive suite of clinical end points, including measures of health status

167 to understand the association of steps with clinical end points, including mortality.

168 he relationships of demographic variables to clinical end points, including perioperative (30-day) ev

169 umab resulted in significant improvements in clinical end points, including physician-assessed and de

170 s plus change in LVEF for predicting 4 major clinical end points, including the trial's primary end p

171 reviously been measured against a variety of clinical end points, including virus acquisition, system

172 TB biomarkers in different populations with clinical end points is essential to the development of a

173 re of tumor clonal dynamics leading to these clinical end points is poorly understood, and previously

174 cutoff in larger groups with correlation to clinical end points is required.

175 pression in PBLs was not associated with any clinical end point measured.

176 um of box (CDR-SB) score was used as primary clinical end point measurement in both studies.

177 d to adenosine tended to reach the composite clinical end point more often than those assigned to pla

178 A combined clinical end point occurred equally in all the groups.

179 The composite clinical end point occurred in 12.8% (51/400) of patient

180 The composite clinical end point occurred less often after endoscopic

181 Each of the clinical end points occurred between 1.9- and 3.5-fold m

182 te subjects for association with the primary clinical end point of asthma exacerbations and changes i

183 Eighteen patients reached the defined clinical end point of death or listing for urgent heart

184 At 1 year, the primary clinical end point of major cardiac events was 63% in th

185 The primary clinical end point of the study was the occurrence of ma

186 ith patient-reported outcomes as the primary clinical end point of the trial.

187 Clinical end points of interest were the success and com

188 subgroup associations were examined with the clinical end points of kidney failure, the composite out

189 ess the relationship of TRA with in-hospital clinical end points of major bleeding, transfusion, and

190 in a manner that correlates with established clinical end points of mortality and major adverse cardi

191 ight the need to further compare imaging and clinical end points of PD progression in long-term studi

192 l failure (IBF) was evaluated in relation to clinical end points of prostate cancer-specific survival

193 condary outcome was a composite index of the clinical end points of reduction in GFR of more than 50%

194 are-metal stents; we then analyzed the major clinical end points of the trials.

195 cohort trials with surrogate or intermediate clinical end points or on non-inferiority trials, as wel

196 did not differ in terms of the EAST primary clinical end points over 3 years.

197 nrolling 50 patients or fewer, those without clinical end points, papers published in a language othe

198 For all clinical end points, participant-reported data contribut

199 The clinical end point (PD < 5 mm, absence of BoP and/or SUP

200 n arbitrary features, consensus criteria for clinical end points provide consistency across studies t

201 between wine consumption, fatal and nonfatal clinical end points, quality of life, symptoms of depres

202 Clinical end point rates and reductions were similar in

203 At a median 24-months of follow-up, our clinical end point rates were 9% for local/regional recu

204 the relative contribution of data sources to clinical end-point rates is understudied.

205 a protocol, and was assessed by nurses using clinical end points rather than a sedation scale.

206 on PFS, suggesting that MRD may be an early clinical end point reasonably likely to predict clinical

207 nimide ester polyethylene glycol (OT-58)] on clinical end points relevant to human patients with HCU.

208 en though data supporting a benefit for hard clinical end points remain limited.

209 Although clinical end points remain the definitive measure of the

210 of high-quality care and enacting changes in clinical end points remains unclear.

211 Our aim was to determine whether these clinical end point results are also associated with chan

212 cine radiologist (blinded to correlative and clinical end points) reviewed all equivocal PET/CT and B

213 83 (88%), respectively, reached the primary clinical end point (risk difference, -4.8% [1-sided 95%

214 cost per patient for each drug, the primary clinical end point studied in each trial; the study's de

215 Clinical end point studies on thromboprophylaxis with di

216 Although this trial was not designed as a clinical end-point study, patients assigned to zidovudin

217 rticle, our focus is when all components are clinical end points such as death or hospitalizations an

218 to assess response in relation to important clinical end points such as fracture.

219 ial fibrillation (AF) in a way that reflects clinical end points such as response to therapy.

220 major adverse cardiac events, and individual clinical end points such as stent thrombosis, cardiac de

221 tigate the association between PRS and other clinical end points such as treatment initiation.

222 om clinical trials was inconclusive on major clinical end points, such as cardiovascular mortality.

223 dy as well as the effect of acetazolamide on clinical end points, such as duration of mechanical vent

224 dromic variability to neuropathology and key clinical end points, such as survival.

225 Despite positive clinical end points targeting depression and anxiety, co

226 in clinical trials; and (4) delineation of a clinical end point that is an accurate measure of the un

227 There is a need for validated clinical end points that are reliably able to quantify p

228 on-resistant prostate cancer (CRPC) need new clinical end points that are valid surrogates for surviv

229 on of emerging insights from the genome into clinical end points that can affect the practice of canc

230 appa agreement statistic of claims to detect clinical end points through 2 years in trial patients.

231 re derived and correlated with the surrogate clinical end points time to first therapy (TTFT) and tim

232 nfocal microscopy may provide an informative clinical end point to evaluate the efficacy of experimen

233 d is not suitable for use as an intermediate clinical end point to substitute for OS to accelerate ph

234 and women have not been well represented in clinical end point trials of pharmacologic lipid-lowerin

235 Unlike clinical end point trials, in which early clinical respo

236 ntibodies incremental to statins in on-going clinical end point trials.

237 cal outcomes requires confirmation in larger clinical end point trials.

238 Clinical end-point trials will be necessary to determine

239 ions between AD biomarkers and cognitive and clinical end points using random-effects meta-regression

240 ing the effects of new therapies on multiple clinical end points using the average Z score enables de

241 delines, determined their risk of reaching a clinical end point (valve replacement for symptoms, hosp

242 e influence of increasing site enrollment on clinical end points varied across geographic regions wit

243 rimary end point, defined as vessel-oriented clinical end point (VOCE) at 2 years, was a composite of

244 ears (P =.006) and a 48% reduced risk of the clinical end points vs the amlodipine group (95% confide

245 trength of their associations with different clinical end points warrants investigation.

246 The clinical end point was 2-year target-lesion failure, a c

247 The frequency of the clinical end point was 24 percent with placebos; 3 perce

248 The primary clinical end point was 90-day dichotomized modified Rank

249 Primary clinical end point was a composite of cardiovascular dea

250 The clinical end point was all-cause mortality.

251 The key secondary clinical end point was at least a 95% posterior probabil

252 The clinical end point was defined as a composite of death,

253 The clinical end point was ischemic stroke.

254 The primary clinical end point was lower in the pharmacoinvasive coh

255 The primary clinical end point was mortality within 6 months after t

256 After 30 days, the primary clinical end point was not significantly different betwe

257 A strong combined genotype effect on each clinical end point was observed.

258 The primary clinical end point was overall survival from the date of

259 The primary clinical end point was the earliest occurrence of pulmon

260 Clinical end point was the improvement of National Insti

261 The clinical end point was the occurrence of major adverse c

262 The primary clinical end point was the occurrence of major adverse c

263 The primary clinical end point was the occurrence of major adverse c

264 The association of galectin-3 with clinical end points was assessed by Cox proportional haz

265 ariables, plasma and urinary biomarkers, and clinical end points was established.

266 However, the frequency of clinical end points was similar in the subgroup with the

267 At 2-year follow-up, no differences in clinical end point were observed between groups.

268 procedures and 24% reduction in a composite clinical end point were observed in patients assigned to

269 Hazard ratios and CIs for a combined clinical end point were recorded for LGE presence, exten

270 Clinical end points were AD dementia and any type of dem

271 Clinical end points were analyzed according to baseline

272 Clinical end points were assessed at 52 weeks.

273 ORs for the 4 clinical end points were calculated for each trial.

274 Clinical end points were defined as overall response rat

275 ctively), neither the 30-day nor the 6-month clinical end points were different among the three group

276 Clinical end points were estimated from time of SRS comp

277 Seven prespecified aggregate clinical end points were examined on an intention-to-tre

278 The primary clinical end points were incidence, cumulative rupture r

279 The clinical end points were ischemic stroke (fatal or nonfa

280 Data on major clinical end points were limited.

281 Clinical end points were measured with 5000-mg double-bl

282 lammation (including cytokines), and 3-month clinical end points were performed in groups with or wit

283 Clinical end points were pooled in meta-analyses that ap

284 The primary clinical end points were progression-free survival (PFS)

285 Clinical end points were recorded at 30 days and six mon

286 None of the 7 other prespecified secondary clinical end points were significantly different.

287 Long-term clinical end points were similar between groups 1 and 2.

288 The clinical end points were sinus rhythm (SR), death, strok

289 Secondary clinical end points were the length of hospital stay, th

290 Clinical end points were toxicity and rates of objective

291 Secondary clinical end points were weight, lean body mass, muscle

292 Clinical end-points were evaluated including frequency o

293 ese three subgroups, when linked with future clinical end points, were associated with different risk

294 cribe recent methods for combining different clinical end points, which take into account the time a

295 g of protective immune responses for a given clinical end point will inform immunogen selection and g

296 termining the correlation of an intermediate clinical end point with OS and the correlation of treatm

297 Comparative treatment effects on clinical end points with dapagliflozin versus placebo we

298 mproved prognostic discrimination across all clinical end points with respect to IPSS-R (concordance

299 there were no significant differences in the clinical end points with torsemide versus furosemide acr

300 bability was significantly prognostic of all clinical end points, with 8-year C indices of 0.63 (95%